In-House vs Third-Party Dental Financing: How to Choose

Most articles about patient financing argue about whether a practice should offer it at all. That is the wrong question, and it has been the wrong question for years. The real decision is structural: does the practice carry the paper itself, or hand it to an outside provider? Those two choices put the default risk, the collections work, and the timing of the cash in completely different places.

Getting that choice right matters more in 2026 than it did three years ago. The ADA Health Policy Institute's Q4 2025 update reported that consumer dental spending grew about 4% year over year as of September 2025, while equipment and supply costs rose about 5% year to date and reimbursement rates stayed flat. That combination squeezes margin on insured procedures and pushes more of a practice's profit into elective, high-ticket cosmetic work. Which is exactly the work where the price objection decides the outcome.

What is the difference between in-house and third-party dental financing?

In-house financing means the practice extends the payment plan itself and collects over time, so it keeps control of the terms and carries the risk that the patient stops paying. Third-party financing means an outside provider approves the patient, pays the practice, and owns the repayment relationship from there, subject to that provider's approval.

There is a third option people fold into this conversation that is not financing at all: paying in full at the chair by card or digital wallet. That is just collection, and for a meaningful share of cosmetic cases it is what actually happens once the patient decides. Keeping it separate in your head matters, because the tooling and the fees are different.

So the question is not whether financing is good. It is where you want the risk, the cash timing, and the administrative work to live.

How does in-house financing actually work for a practice?

The practice sets a schedule, usually splitting the case fee into payments over a defined period, and bills the patient directly. There is no outside approval step, which means nothing gets declined in the operatory while the patient is sitting there.

The upside is real control. You set the terms, you can make an exception for a long-standing patient, and the relationship stays entirely inside the practice. Nobody at the front desk has to explain a third party's decision.

The cost is that the practice becomes the bank. It funds the treatment before it is paid for, it absorbs the loss when a patient stops paying, and somebody in the office now owns collections as a real job with real hours. That last part gets underestimated constantly. A payment plan is not a one-time conversation, it is a recurring administrative obligation for the length of the plan.

One honest caveat: extending payment terms to consumers can carry lending and state-law implications depending on how the plan is structured. This post is not legal advice. Before a practice sets up an in-house plan, it should have its own counsel look at the structure.

How does third-party financing work, and what does it cost?

An outside provider approves the patient, pays the practice, and collects from the patient over time. The practice pays a processing fee on the transaction and is otherwise out of the repayment business entirely.

The upside is that cash lands quickly and default risk moves off the practice's books. If the patient stops paying the provider, that is between the patient and the provider. Nobody in the office is making collection calls.

The cost has two parts. First, a per-transaction fee the practice pays. Second, an approval step that can decline, which is a live failure mode in front of the patient. Approval is never guaranteed, and the terms a patient receives vary by provider and by that patient's own situation.

Here is a concrete version so the fee side is not abstract. Smile PreVue surfaces both paths in the same place: pay in full by card, Apple Pay, Google Pay, or Cash App, or pay over time through Affirm, Klarna, or Sunbit, all running through Stripe. Smile PreVue is not a lender or a bank. Founding-member practice processing is 3.2% per card transaction and 6.5% on financed cases. Those are the practice's processing rates, not the patient's terms, and the patient's actual repayment terms come from the provider and are always subject to that provider's approval.

Which one should a practice choose?

The tradeoff is easier to see side by side than in prose.

Question	In-house plan	Third-party financing	Pay in full at the chair
Who carries default risk	The practice	The financing provider	Nobody, it is settled
When the practice gets paid	Over the plan's life	Shortly after the case	Immediately
Who does collections	The practice	The provider	No collections
Who sets the terms	The practice	The provider	Not applicable
What can fail at the chair	Nothing, no approval step	The patient can be declined	The card can decline
Best fit	Small volume, strong front office, established patients	High case value, thin admin capacity	Patients who were always going to pay outright

A few decision rules fall out of that table.

High case values combined with a thin front office point strongly toward third party. When one person is running scheduling, insurance, and recall, adding a collections function is not a neutral decision, it is a new job nobody has time for.

A small number of long-standing patients plus genuine administrative bandwidth can make in-house workable. If you know your patients well, your default rate is probably lower than the industry-wide numbers suggest, and you keep the fee.

Most practices end up offering more than one. That is not indecision, it is correct. Different patients arrive with different constraints, and having a single option means the ones it does not fit walk out undecided.

Why does financing structure affect case acceptance at all?

Here is the mechanic that makes this a case-acceptance topic rather than an accounting one. A treatment plan the patient wants but cannot immediately afford does not turn into a no. It turns into a maybe. And a maybe leaves the building.

Timing matters more than structure. Whichever way a practice chooses to handle it, the payment option has to exist in the same visit as the plan, priced, while the patient is still looking at what they are buying. A financing conversation scheduled for later is a case that cools off between now and then. The enthusiasm the patient felt in the chair does not survive the drive home, the calendar, and the four other things competing for that money.

This is also why patient payments and financing belongs in the same moment as the visual, not in a separate step at the front desk. A patient who has seen a likely result of the treatment is deciding about a specific outcome they want. A patient who has only seen a number on a printout is deciding about a number. Those are two very different decisions, and only one of them is easy to say yes to.

It is worth naming what this is not. Digital Smile Design is a design and planning system, and a strong one for what it does. It is not a place to price the case and collect for it. The point here is that the visual and the payment conversation are one moment at the chair, not two systems the coordinator has to bridge.

What to check before you commit to either one

Four questions separate a structure that works from one that quietly leaks cases.

• Can the option be presented in the operatory, or does it require walking the patient to the front desk? Every handoff is a chance for the case to stall.
• What does the practice actually net after fees, compared to what it nets after unpaid in-house balances? Those two numbers are more similar than most owners expect.
• Does the patient-facing language stay compliant? No promised approval, no quoted APRs, no "no credit check" claims. That is not just good practice, it is the kind of thing that draws regulatory attention.
• Does the tooling price the plan and present the payment option in one place, or does it take three systems? The answer changes how many cases actually get to a decision.

Frequently asked questions

Does offering financing actually increase case acceptance? It removes a specific objection. It does not create demand. A patient who does not want the treatment will not be talked into it by a payment plan, and a patient who wants it but is stuck on affordability now has a path. Expect the second group to move, not the first.

Is in-house financing cheaper than third-party? Only if the practice collects everything it bills. Compare the processing fee you would pay against your realistic uncollected balance plus the staff hours collections consumes.

Can a practice offer both? Yes, and most do. Offering only one structure means the patients it does not fit leave undecided.

Does Smile PreVue lend money to patients? No. Smile PreVue is not a lender or a bank. Card and wallet payments run through Stripe, and pay-over-time is provided by Affirm, Klarna, or Sunbit, always subject to that provider's approval.

How fast does a practice get paid with third-party financing? The provider pays the practice, so the practice is not waiting on the patient's payment schedule.

The part that actually moves the number

Whichever structure you land on, the constraint is the same: the patient has to be able to see the outcome and see the path to paying for it in the same visit, before the enthusiasm cools.

Smile PreVue puts both in one place on an iPad, with no hardware to buy and about a ten-minute setup. Start a 3-day free trial and run it on your next cosmetic consult.